SecBot SecBot
SECBOTREPLAY Home › Report › VOR

VOR · Vor Bio reported Q2 2026 financial results with net loss of $62.8M,…

Vor Biopharma · PRESS-RELEASE filed Aug 11, 2026 at 09:30 ET

At the news

NEUTRALIMPACT 3/10

PRESS-RELEASE filed Aug 11, 2026 at 09:30 ET

Vor Bio reported Q2 2026 financial results with net loss of $62.8M, cash of $466.1M (plus $48.4M from July ATM sales), and provided pipeline updates for telitacicept. Phase 3 UPSTREAM MG and UPSTREAM SjD trials are enrolling with topline data expected in 1H27. As a pre-revenue clinical-stage biotech, the filing is a routine quarterly update with no material financial surprises.

  • Cash, cash equivalents and marketable securities were $466.1M as of June 30, 2026, with $48.4M additional net proceeds from ATM sales in July 2026, providing runway into early 2029.
  • Net loss for Q2 2026 was $62.8M, compared to $1,573.7M in Q2 2025 (decrease primarily due to change in fair value of liability-classified warrants).
  • R&D expenses were $25.9M vs $261.5M in Q2 2025; G&A expenses were $21.9M vs $12.8M.
  • Enrollment ongoing in global Phase 3 UPSTREAM MG trial for generalized myasthenia gravis and UPSTREAM SjD trial for primary Sjögren's disease, with topline data from UPSTREAM MG anticipated in 1H27.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access